We are aware of current issues with the ONS login. Please clear your device history/cache/cookies before attempting to log in. Thank you for your patience as we address this issue.

Oncology Drug Reference Sheet: Radium 223 Dichloride

By: Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®

Published In: Voice

Publication Date: 2019-12-24

Description

Radium 223 dichloride (Xofigo^®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

View Article @ voice.ons.org

ONS Drug Education

Short summaries of newly approved oncology-related therapies or drugs with new indications.

View All Drug Education

Oncology Drug Reference Sheet: Radium 223 Dichloride

Description

ONS Drug Education

Related Topics